Working paper Open Access

Ivermectin for Covid-19

Sparavigna, Amelia Carolina


MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="041" ind1=" " ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Covid-19</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Ivermectin</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Hydroxychloroquine</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Doxycycline</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">azithromycin</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Covid-19 rare symptoms</subfield>
  </datafield>
  <controlfield tag="005">20200730005925.0</controlfield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Before reading this work, please consider that I am not a physician. I do not suggest the use of ivermectin. I am not touting this drug. This analysis of publications and news about ivermectin is made in the framework of a wider investigation about information concerning drugs used for Covid-19.</subfield>
  </datafield>
  <controlfield tag="001">3965910</controlfield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">496872</subfield>
    <subfield code="z">md5:67d1ad25157a1b7ec83341539eb629d6</subfield>
    <subfield code="u">https://zenodo.org/record/3965910/files/Ivermectin-17.pdf</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2020-07-29</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">openaire</subfield>
    <subfield code="p">user-covid-19</subfield>
    <subfield code="p">user-zenodo</subfield>
    <subfield code="o">oai:zenodo.org:3965910</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">Politecnico di Torino</subfield>
    <subfield code="0">(orcid)0000-0003-4502-8974</subfield>
    <subfield code="a">Sparavigna, Amelia Carolina</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Ivermectin for Covid-19</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-covid-19</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-zenodo</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u">https://creativecommons.org/licenses/by/4.0/legalcode</subfield>
    <subfield code="a">Creative Commons Attribution 4.0 International</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">&lt;p&gt;Discussion of scholarly papers published on Ivermectin, starting from the article of Caly et al. in Antiviral Research, available online April 3, 2020, and of some news that we can find about the use of this drug for the treatment of Covid-19. A list of clinical trials is also given. The proposed discussion was made in a series of versions from 14 June this of 29 July 2020.&amp;nbsp; For what concerns scholarly papers, we report among them two preprints in MedR&amp;chi;iv. One,&amp;nbsp; posted on 10 June,&amp;nbsp; concludes that Ivermectin was associated with lower mortality during treatment of Covid-19.&amp;nbsp; The other preprint, posted on 8 July, is showing the result of a clinical trial. This preprint tells, in its conclusions that add-on use of Ivermectin is giving better results when compared to controls, in particular a significant shorter hospitalization. A preprint, posted in Research Square on July 14, is reported too. This preprint is giving the result of a trial regarding the combinations Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin. Among news, we consider especially the news regarding the use of Ivermectin in Peru. The case of Iquitos is discussed in detail. In Iquitos, capital of the Department of Loreto, by May 25 Covid-19 cases and deaths had dropped notably, as reported on the web. Epidemic data in this region are considered. Recent news (July 27), displaying the observation of&amp;nbsp; rare symptoms of Covid-19, is also reported in detail. The observation was related to a set of more than 3,000 patients in Lima. The formulation of Ivermectin used in Peru is also discussed, in particular that of the oral solution, disclosed by the Peruvian Government.&amp;nbsp;&lt;/p&gt;</subfield>
  </datafield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="n">doi</subfield>
    <subfield code="i">isVersionOf</subfield>
    <subfield code="a">10.5281/zenodo.3893750</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.5281/zenodo.3965910</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">workingpaper</subfield>
  </datafield>
</record>
3,957
1,371
views
downloads
All versions This version
Views 3,957355
Downloads 1,37191
Data volume 355.3 MB45.2 MB
Unique views 3,242320
Unique downloads 1,14173

Share

Cite as